Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee (DSMC) to Accelerate 177Lu-RAD202 Phase 1 ‘HEA…

Phase 1 study to progress to the next dose level of 75mCi in patients with HER2+ advanced solid tumors, instead of the ...